Received Jun 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | OT |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | OT |
a 37 year old female patient received her first dose of the GARDASIL 9 vaccine on 11/28/2023. The patient received her second dose of the GARDASIL 9 vaccine on 05/28/2025; No additional AE; Information has been received from Business Partner/CRO on 28-May-2025. This spontaneous report was received from a/an Pharmacist and refers to a(n) 37-year-old female patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 28-Nov-2023, the patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9),, dose number 1, (first dose), administered by Unknown route (lot # and expiration date were not reported). On 28-May-2025, the patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9),, dose number 2, (second dose), administered by Unknown route (lot # and expiration date were not reported). The patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), for the treatment of prophylaxis. On an unknown date, the patient experienced a 37 year old female patient received her first dose of the GARDASIL 9 vaccine on 11/28/2023. The patient received her second dose of the GARDASIL 9 vaccine on 05/28/2025. On an unknown date, the patient experienced No additional AE. At the reporting time, the outcome of a 37 year old female patient received her first dose of the GARDASIL 9 vaccine on 11/28/2023. The patient received her second dose of the GARDASIL 9 vaccine on 05/28/2025 and No additional AE was unknown. The action taken with Human Papillomavirus 9-valent Vaccine, Recombinant was reported as not applicable.